ClinicalTrials.gg

TargetBeta

ADRA1A

adrenoceptor alpha 1A · also ADRA1L1, ADRA1C · Adrenoceptors

7 programs in company-led studies act on ADRA1A, from 6 companies: 1 in phase 3, 6 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (7 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
TamsulosinruleBoehringer Ingelheimphase 4605 runningADRA1B, ADRA1DChEMBL
EpinephrineruleNasus Pharmaphase 4175 runningADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3ChEMBL
OxymetazolineruleAbbViephase 4201 runningADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2CChEMBL
PhentolamineruleOpus Geneticsphase 4181 runningADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2CChEMBL
silodosinruleAbbViephase 4170 running–ChEMBL
MidodrineruleTakedaphase 4100 runningADRA1B, ADRA1DChEMBL
PrazosinrulePfizerphase 340 runningADRA1B, ADRA1DChEMBL

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.